FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Hans Tesch

Research Profile

Disorders

Procedures

Anatomy

Chemicals & Drugs

Living Beings

Human Herpesvirus 4

Genes & Molecular Sequences

Proto-Oncogenes

Concepts & Ideas

Co-author Network

Publications

TOP 3
Michael P Lux; Achim Wöckel; Agnes Benedict; Stefan Buchholz; Noémi Kreif; Nadia Harbeck; Rolf Kreienberg; Manfred Kaufmann; Matthias W Beckmann; Walter Jonat; Peyman Hadji; Wolfgang Distler; Guenther Raab; Hans Tesch; Georg Weyers; Kurt Possinger; Andreas Schneeweiss
Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system.
Andreas Engert; Jeremy Franklin; Hans Theodor Eich; Corinne Brillant; Susanne Sehlen; Claudio Cartoni; Richard Herrmann; Michael Pfreundschuh; Markus Sieber; Hans Tesch; Astrid Franke; Peter Koch; Maike de Wit; Ursula Paulus; Dirk Hasenclever; Markus Loeffler; Rolf-Peter Müller; Hans Konrad Müller-Hermelink; Eckhart Dühmke; Volker Diehl
Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
Martina Vockerodt; Diana Pinkert; Sigrun Smola-Hess; Astrid Michels; Richard M Ransohoff; Hans Tesch; Martin Hafner
The Epstein-Barr virus oncoprotein latent membrane protein 1 induces expression of the chemokine IP-10: importance of mRNA half-life regulation.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Hans Tesch (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Michael P Lux; Achim Wöckel; Agnes Benedict; Stefan Buchholz; Noémi Kreif; Nadia Harbeck; Rolf Kreienberg; Manfred Kaufmann; Matthias W Beckmann; Walter Jonat; Peyman Hadji; Wolfgang Distler; Guenther Raab; Hans Tesch; Georg Weyers; Kurt Possinger; Andreas Schneeweiss
Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system.
Onkologie 2010;33(4):155-66.
2007: Andreas Engert; Jeremy Franklin; Hans Theodor Eich; Corinne Brillant; Susanne Sehlen; Claudio Cartoni; Richard Herrmann; Michael Pfreundschuh; Markus Sieber; Hans Tesch; Astrid Franke; Peter Koch; Maike de Wit; Ursula Paulus; Dirk Hasenclever; Markus Loeffler; Rolf-Peter Müller; Hans Konrad Müller-Hermelink; Eckhart Dühmke; Volker Diehl
Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(23):3495-502.
2005: Martina Vockerodt; Diana Pinkert; Sigrun Smola-Hess; Astrid Michels; Richard M Ransohoff; Hans Tesch; Martin Hafner
The Epstein-Barr virus oncoprotein latent membrane protein 1 induces expression of the chemokine IP-10: importance of mRNA half-life regulation.
International journal of cancer. Journal international du cancer 2005;114(4):598-605.
2004: Eva-Maria Schneider; Emina Torlakovic; Albert Stühler; Volker Diehl; Hans Tesch; Bernd Giebel
The early transcription factor GATA-2 is expressed in classical Hodgkin's lymphoma.
The Journal of pathology 2004;204(5):538-45.
2004: Roman K Thomas; Claudia Wickenhauser; Martin Hafner; Hans Tesch; Volker Diehl; Jürgen Wolf; Martina Vockerodt
Repeated clonal relapses in classical Hodgkin's lymphoma and the occurrence of a clonally unrelated diffuse large B cell non-Hodgkin lymphoma in the same patient.
Leukemia & lymphoma 2004;45(5):1065-9.
2004: Martin R Weihrauch; Peter Staib; Bettina Seiberlich; Martin Hoffmann; Volker Diehl; Hans Tesch
Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia.
Leukemia & lymphoma 2004;45(4):699-704.
2003: Volker Diehl; Jeremy Franklin; Michael Pfreundschuh; Bernd Lathan; Ursula Paulus; Dirk Hasenclever; Hans Tesch; Richard Herrmann; Bernd Dörken; Hans Konrad Müller-Hermelink; Eckhart Dühmke; Markus Loeffler
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
The New England journal of medicine 2003;348(24):2386-95.
2003: Martin R Weihrauch; Markus Dietlein; Harald Schicha; Volker Diehl; Hans Tesch
Prognostic significance of 18F-fluorodeoxyglucose positron emission tomography in lymphoma.
Leukemia & lymphoma 2003;44(1):15-22.
2002: Martina Vockerodt; Gazanfer Belge; Martin Hafner; Johannes Irsch; Reiner Siebert; Hans Tesch; Volker Diehl; Jürgen Wolf; Jörn Bullerdiek; Andrea Staratschek-Jox
An unbalanced translocation involving chromosome 14 is the probable cause for loss of potentially functional rearranged immunoglobulin heavy chain genes in the Epstein-Barr virus-positive Hodgkin's lymphoma-derived cell line L591.
British journal of haematology 2002;119(3):640-6.
2002: Markus Sieber; Hans Tesch; Beate Pfistner; Ulrich Rueffer; Bernd Lathan; Oana Brosteanu; Ursula Paulus; Tina Koch; Michael Pfreundschuh; Markus Loeffler; Andreas Engert; Andreas Josting; Jürgen Wolf; Dirk Hasenclever; Jeremy Franklin; Eckhart Duehmke; Axel Georgii; Klaus-Peter Schalk; Hartmut Kirchner; Gottfried Doelken; Reinhold Munker; Peter Koch; Richard Herrmann; richard greil; Anna Paola Anselmo; Volker Diehl
Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(2):476-84.
2002: Martin R Weihrauch; Edmund Skibowski; Andreas Draube; Andrea Geller; Hans Tesch; Volker Diehl; Heribert Bohlen
Immunomagnetic enrichment and detection of isolated tumor cells in bone marrow of patients with epithelial malignancies.
Clinical & experimental metastasis 2002;19(7):617-21.
2002: Martin R Weihrauch; Daniel Re; S Bischoff; Markus Dietlein; Klemens Scheidhauer; Barbara Krug; F Textoris; Sascha Ansén; Jeremy Franklin; Heribert Bohlen; Jürgen Wolf; Harald Schicha; Volker Diehl; Hans Tesch
Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease.
Annals of hematology 2002;81(1):20-5.
2001: Martina Vockerodt; Hans Tesch; Martin Hafner
Epstein-Barr virus latent membrane protein-1 activates CD25 expression in lymphoma cells involving the NFkappaB pathway.
Genes and immunity 2001;2(8):433-41.
2001: Martin R Weihrauch; Daniel Re; Klemens Scheidhauer; Sascha Ansén; Markus Dietlein; S Bischoff; Heribert Bohlen; Jürgen Wolf; Harald Schicha; Volker Diehl; Hans Tesch
Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease.
Blood 2001;98(10):2930-4.
2001: Martin R Weihrauch; K Rabe; Matthias Kochanek; Hans Tesch; Volker Diehl; Jürgen Wolf
[Factitious disorders. Hematologic, neurologic and dermatologic symptoms in a physician with factitious disorder].
Medizinische Klinik (Munich, Germany : 1983) 2001;96(9):555-60.
2001: Ulrich Rueffer; Kai Breuer; Andreas Josting; Bernd Lathan; Markus Sieber; Oliver Manzke; FJ Grotenhermen; Hans Tesch; Henning Bredenfeld; Peter Koch; Hiltrud Nisters-Backes; Jürgen Wolf; Andreas Engert; Volker Diehl
Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(9):1307-11.
2001: Martin Hafner; U Holtick; Martina Vockerodt; Tahamtan Ahmadi; B Haier; I Behrmann; P C Heinrich; Volker Diehl; Hans Tesch
STAT3 is constitutively activated in Hodgkin cell lines.
Blood 2001;98(3):762-70.
2001: Johannes Irsch; Jürgen Wolf; Hans Tesch; Volker Diehl; Andreas Radbruch; Andrea Staratschek-Jox
Class switch recombination was specifically targeted to immunoglobulin (Ig)G4 or IgA in Hodgkin's disease-derived cell lines.
British journal of haematology 2001;113(3):785-93.
2001: Michael Pfreundschuh; Dirk Hasenclever; Markus Loeffler; G Ehninger; Norbert Schmitz; Hartmut Kirchner; Peter Koch; Bernd Lathan; Ulrich Rueffer; Michael Sextro; Jeremy Franklin; Hans Tesch; Volker Diehl
Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(4):471-7.
2001: Oliver Manzke; Hans Tesch; Johann Lorenzen; Volker Diehl; Heribert Bohlen
Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. II. Assessment of cellular immune responses.
International journal of cancer. Journal international du cancer 2001;91(4):516-22.
2001: Oliver Manzke; Hans Tesch; Peter Borchmann; Jürgen Wolf; K Lackner; Axel Gossmann; Volker Diehl; Heribert Bohlen
Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. I. Clinical phase I evaluation.
International journal of cancer. Journal international du cancer 2001;91(4):508-15.
2001: Martina Vockerodt; B Haier; P Buttgereit; Hans Tesch; Martin Hafner
The Epstein-Barr virus latent membrane protein 1 induces interleukin-10 in Burkitt's lymphoma cells but not in Hodgkin's cells involving the p38/SAPK2 pathway.
Virology 2001;280(2):183-98.
2001: Andreas Draube; R Pfister; Martina Vockerodt; S Schuster; Martin Hafner; Volker Diehl; Hans Tesch
Immunomagnetic enrichment of CD138 positive cells from weakly infiltrated myeloma patients samples enables the determination of the tumor clone specific IgH rearrangement.
Annals of hematology 2001;80(2):83-9.
2000: G Jung; Walter Heindel; Michael S von Bergwelt-Baildon; Henning Bredenfeld; Axel Gossmann; Markus Zähringer; Hans Tesch
Abdominal lymphoma staging: is MR imaging with T2-weighted turbo-spin-echo sequence a diagnostic alternative to contrast-enhanced spiral CT?
Journal of computer assisted tomography 2000;24(5):783-7.
2000: A Santoro; Henning Bredenfeld; liliana devizzi; Hans Tesch; Valeria Bonfante; Simonetta Viviani; F Fiedler; H S Parra; C Benoehr; M Pacini; Gianni Bonadonna; Volker Diehl
Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(13):2615-9.
2000: Hans Tesch; Andreas Engert; Oliver Manzke; Volker Diehl; Heribert Bohlen
Treatment of patients with malignant lymphomas with monoclonal antibodies.
Bone marrow transplantation 2000;25 Suppl 2():S50-3.
2000: Jeremy Franklin; Ursula Paulus; D Lieberz; Kai Breuer; Hans Tesch; Volker Diehl
Is the international prognostic score for advanced stage Hodgkin's disease applicable to early stage patients? German Hodgkin Lymphoma Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(5):617-23.
2000: L Mantovani; G Lentini; B Hentschel; PD Wickramanayake; Markus Loeffler; Volker Diehl; Hans Tesch
Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin.
British journal of haematology 2000;109(2):367-75.
2000: Heribert Bohlen; M Kessler; Michael Sextro; Volker Diehl; Hans Tesch
Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease.
Annals of hematology 2000;79(3):110-3.
2000: S Titzer; O Christensen; Oliver Manzke; Hans Tesch; Jürgen Wolf; Bertold Emmerich; C Carsten; Volker Diehl; Heribert Bohlen
Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects.
British journal of haematology 2000;108(4):805-16.
2000: Andreas Josting; M Reiser; PD Wickramanayake; Ulrich Rueffer; Andreas Draube; Dietmar Söhngen; Hans Tesch; Jürgen Wolf; Volker Diehl; Andreas Engert
Dexa-BEAM: an effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed/refractory mantle-cell lymphoma.
Leukemia & lymphoma 2000;37(1-2):185-7.
2000: Andreas Josting; M Reiser; PD Wickramanayake; Ulrich Rueffer; Andreas Draube; Dietmar Söhngen; Hans Tesch; Jürgen Wolf; Volker Diehl; Andreas Engert
Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.
Leukemia & lymphoma 2000;37(1-2):115-23.
2000: Daniel Re; Achim Schwenk; P Hegener; SU Bamborschke; Volker Diehl; Hans Tesch
Guillain-Barré syndrome in a patient with non-Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(2):217-20.
2000: D Lieberz; Michael Sextro; Ursula Paulus; Jeremy Franklin; Hans Tesch; Volker Diehl
How to restrict liver biopsy to high-risk patients in early-stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group.
Annals of hematology 2000;79(2):73-8.
2000: Beate Pfistner; Ursula Paulus; Jan-Peter Glossmann; R Walshe; Hans Tesch; Volker Diehl
Can factors influencing in-patient treatment in Hodgkin's disease be identified?--Retrospective analysis of HD6 patients of the GHSG.
Studies in health technology and informatics 2000;77():399-403.
1999: Martin Hafner; Heike Laser; A von Knethen; Hans Tesch
The AT-rich region between -54 to -66 is important for the promoter activity of interleukin-10 in Epstein-Barr virus positive Burkitt's lymphoma cells.
Genes and immunity 1999;1(2):105-14.
1999: Ulrich Rueffer; Markus Sieber; Andreas Josting; Kai Breuer; FJ Grotenhermen; Henning Bredenfeld; Hans Tesch; Hiltrud Nisters-Backes; Andreas Engert; Volker Diehl
Prognostic factors for subdiaphragmatic involvement in clinical stage I-II supradiaphragmatic Hodgkin's disease: a retrospective analysis of the GHSG.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(11):1343-8.
1999: H T Steinmetz; A Schulz; Peter Staib; Christof Scheid; A Glasmacher; A Neufang; Jeremy Franklin; Hans Tesch; Volker Diehl; P Dias Wickramanayake
Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML.
Annals of hematology 1999;78(9):418-25.
1999: Martin Kornacker; A Jox; Martina Vockerodt; Hans Tesch; Heribert Bohlen; Volker Diehl; Jürgen Wolf
Detection of a Hodgkin/Reed-Sternberg cell specific immunoglobulin gene rearrangement in the serum DNA of a patient with Hodgkin's disease.
British journal of haematology 1999;106(2):528-31.
1999: Johannes Irsch; C König; A Löhndorf; Hans Tesch; Thomas Krieg; H Merk; Andreas Radbruch; Nicolas Hunzelmann
The frequency of phospholipase A2 binding of basophilic granulocytes does not decrease during bee-venom-specific immunotherapy.
Allergy 1999;54(7):742-7.
1999: M Reiser; Andreas Josting; Andreas Draube; MY Mapara; Christof Scheid; Jens M Chemnitz; Hans Tesch; J Wolf; Volker Diehl; Dietmar Söhngen; Andreas Engert
Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization.
Bone marrow transplantation 1999;23(12):1223-8.
1999: M Reiser; Andreas Josting; P Dias Wickramanayake; Andreas Draube; Christof Scheid; Hans Tesch; Jürgen Wolf; Volker Diehl; Andreas Engert
Dexa-BEAM is not effective in patients with relapsed or resistant aggressive high-grade non-Hodgkin's lymphoma.
Leukemia & lymphoma 1999;33(3-4):305-12.
1999: Oliver Manzke; Frank Berthold; K Huebel; Hans Tesch; Volker Diehl; Heribert Bohlen
CD3xCD19 bispecific antibodies and CD28 bivalent antibodies enhance T-cell reactivity against autologous leukemic cells in pediatric B-ALL bone marrow.
International journal of cancer. Journal international du cancer 1999;80(5):715-22.
1999: P A Horn; Hans Tesch; Peter Staib; D Kube; Volker Diehl; Dimitris Voliotis
Expression of AC133, a novel hematopoietic precursor antigen, on acute myeloid leukemia cells.
Blood 1999;93(4):1435-7.
1999: Daniel Re; SU Bamborschke; W Feiden; Rudolph Schröder; Ralph Lehrke; Volker Diehl; Hans Tesch
Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy.
Bone marrow transplantation 1999;23(3):295-8.
1999: Martin Hafner; Martina Vockerodt; O Weber; K Hell; Jürgen Wolf; B Haier; Friedrich A Grässer; N Müller-Lantzsch; E Kieff; Volker Diehl; Hans Tesch
Expression of epstein-barr virus nuclear antigen 1 is associated with enhanced expression of CD25 in the Hodgkin cell line L428.
Journal of virology 1999;73(2):1630-6.
1999: Daniel Re; Marcel Reiser; SU Bamborschke; Rudolph Schröder; Ralph Lehrke; Hans Tesch; Bernd Salzberger; Volker Diehl; Gerd Fätkenheuer
Two cases of toxoplasmic encephalitis in patients with acute T-cell leukaemia and lymphoma.
The Journal of infection 1999;38(1):26-9.
1998: Hans Tesch; Volker Diehl; Bernd Lathan; Dirk Hasenclever; Markus Sieber; U Rüffer; Andreas Engert; Jeremy Franklin; Michael Pfreundschuh; K P Schalk; G Schwieder; G Wulf; Gottfried Dölken; P Worst; Peter Koch; Norbert Schmitz; U Bruntsch; C Tirier; U Müller; Markus Loeffler
Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group.
Blood 1998;92(12):4560-7.
1998: Volker Diehl; Jeremy Franklin; Dirk Hasenclever; Hans Tesch; Michael Pfreundschuh; Bernd Lathan; Ursula Paulus; Markus Sieber; J U Rueffer; Michael Sextro; Andreas Engert; Jürgen Wolf; R Hermann; L Holmer; U Stappert-Jahn; E Winnerlein-Trump; G Wulf; S Krause; A Glunz; K von Kalle; H Bischoff; C Haedicke; E Duehmke; Axel Georgii; Markus Loeffler
BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(12):3810-21.
1998: Martina Vockerodt; M Soares; H Kanzler; Ralf Küppers; Martin Hafner; Martin-Leo Hansmann; Volker Diehl; Hans Tesch
Detection of clonal Hodgkin and Reed-Sternberg cells with identical somatically mutated and rearranged VH genes in different biopsies in relapsed Hodgkin's disease.
Blood 1998;92(8):2899-907.
1998: Volker Diehl; J Wolf; R Walshe; Hans Tesch; Markus Loeffler
[Therapy of Hodgkin's disease. Optimization over 4 study generations].
Der Internist 1998;39(9):917-26.
1998: Johannes Irsch; S Nitsch; Martin-Leo Hansmann; Klaus Rajewsky; Hans Tesch; Volker Diehl; A Jox; Ralf Küppers; Andreas Radbruch
Isolation of viable Hodgkin and Reed-Sternberg cells from Hodgkin disease tissues.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(17):10117-22.
1998: Andreas Josting; I Kàtay; Ulrich Rueffer; S Winter; Hans Tesch; Andreas Engert; Volker Diehl; PD Wickramanayake
Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(3):289-95.
1998: Hans Tesch; Heribert Bohlen; Jürgen Wolf; Andreas Engert
[Pathogenesis and therapy of Hodgkin lymphoma].
Medizinische Klinik (Munich, Germany : 1983) 1998;93(2):82-90.
1998: Peter Staib; Bernd Lathan; S Knöppel-Schwark; Hans Tesch; Dimitris Voliotis; H T Steinmetz; Martin Schwonzen; PD Wickramanayake; Volker Diehl
Cytosine arabinoside, etoposide and aclarubicin (AVA) for the treatment of acute myeloid leukemia (AML) in elderly patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(2):221-3.
1998: Jürgen Wolf; Hans Tesch; R Parsa-Parsi; Andreas Engert; Volker Diehl
Current clinical trials for the treatment of adult Hodgkin's disease: common strategies and perspectives.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9 Suppl 5():S79-82.
1998: Volker Diehl; Jeremy Franklin; Dirk Hasenclever; Hans Tesch; Michael Pfreundschuh; Bernd Lathan; Ursula Paulus; Markus Sieber; JU Rüffer; Michael Sextro; Andreas Engert; Jürgen Wolf; R Hermann; L Holmer; U Stappert-Jahn; E Winnerlein-Trump; G Wulf; S Krause; A Glunz; K von Kalle; H Bischoff; C Haedicke; Eckhart Dühmke; Axel Georgii; Markus Loeffler
BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9 Suppl 5():S67-71.
1998: Jeremy Franklin; Hans Tesch; Martin-Leo Hansmann; Volker Diehl
Lymphocyte predominant Hodgkin's disease: pathology and clinical implication.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9 Suppl 5():S39-44.
1997: Kai Hübel; Hans Tesch; B Kröger; Roland Schnell; Peter Borchmann; Volker Diehl; Andreas Engert
A phase I/II study of idarubicin, dexamethasone and interferon-alpha (I-Dexa) in patients with relapsed or refractory multiple myeloma.
Leukemia 1997;11 Suppl 5():S47-51.
1997: Oliver Manzke; S Titzer; Hans Tesch; Volker Diehl; Heribert Bohlen
CD3 x CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphoma.
Cancer immunology, immunotherapy : CII 1997;45(3-4):198-202.
1997: Oliver Manzke; Hans Tesch; Volker Diehl; Heribert Bohlen
Single-step purification of bispecific monoclonal antibodies for immunotherapeutic use by hydrophobic interaction chromatography.
Journal of immunological methods 1997;208(1):65-73.
1997: Reinhard von Wasielewski; M Mengel; Robert Fischer; Martin-Leo Hansmann; Klaus Hübner; Jeremy Franklin; Hans Tesch; Ursula Paulus; Martin Werner; Volker Diehl; Axel Georgii
Classical Hodgkin's disease. Clinical impact of the immunophenotype.
The American journal of pathology 1997;151(4):1123-30.
1997: A Von Knethen; H Abts; Martin Hafner; V Diehl; Hans Tesch
Expression of p56lck in B-cell neoplasias.
Leukemia & lymphoma 1997;26(5-6):551-62.
1997: Markus Loeffler; Volker Diehl; Michael Pfreundschuh; Ursula Rühl; Dirk Hasenclever; Hiltrud Nisters-Backes; Markus Sieber; Hans Tesch; Jeremy Franklin; W Geilen; H Bartels; C Cartoni; Gottfried Dölken; J Enzian; R Fuchs; W Gassmann; H Gerhartz; U Hagen-Aukamp; E Hiller; H Hinkelbein; W Hinterberger; Hartmut Kirchner; Peter Koch; B Krüger; EW Schwarze
Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(6):2275-87.
1997: Heribert Bohlen; Oliver Manzke; S Titzer; Johann Lorenzen; Martin Hafner; Andreas Engert; Hinrich Abken; Jürgen Wolf; Volker Diehl; Hans Tesch
Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells.
Cancer research 1997;57(9):1704-9.
1997: Volker Diehl; Markus Sieber; U Rüffer; Bernd Lathan; Dirk Hasenclever; Michael Pfreundschuh; Markus Loeffler; D Lieberz; Peter Koch; M Adler; Hans Tesch
BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(2):143-8.
1997: Andreas Engert; Roland Schnell; Frithjof C Küpper; Marcel Reiser; M Engelhard; M Wilhelm; Bernd Lathan; S Baltes-Engler; B Winterhalter; M E Scheulen; B Dederichs; Hans Tesch; B Wörmann; Volker Diehl
A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin's lymphoma.
Leukemia & lymphoma 1997;24(5-6):513-22.
1997: Andreas Engert; Volker Diehl; Roland Schnell; A Radszuhn; M T Hatwig; S Drillich; G Schön; Heribert Bohlen; Hans Tesch; M L Hansmann; Stefan Barth; John Schindler; Victor Ghetie; Jonathan Uhr; Ellen S Vitetta
A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma.
Blood 1997;89(2):403-10.
1996: Heribert Bohlen; K Thielemanns; Hans Tesch; Andreas Engert; H J Wolf; B van Camp; J Urbain; Volker Diehl
Idiotype vaccination strategies against a murine B-cell lymphoma: dendritic cells loaded with idiotype and bispecific idiotype x anti-class II antibodies can protect against tumor growth.
Cytokines and molecular therapy 1996;2(4):231-8.
1996: Dimitris Voliotis; Hans Tesch
[Experimental approaches].
Der Internist 1996;37(10):1040-8.
1996: S C Klein; Martin Hafner; Harry F Abts; Volker Diehl; Hans Tesch
Promotion of IL8, IL10, TNF alpha and TNF beta production by EBV infection.
Leukemia research 1996;20(8):633-6.
1996: Hans Tesch; Volker Diehl
Hodgkin's disease: from basic science to clinical application.
Leukemia 1996;10 Suppl 2():s74-7.
1996: U Winkler; Heribert Bohlen; V Schirrmacher; G Schlimok; Dimitris Voliotis; M Brach; N Niederle; Hans Tesch; Volker Diehl; Andreas Engert
[Immunotherapy of hemato-oncologic diseases].
Medizinische Klinik (Munich, Germany : 1983) 1996;91(4):226-33.
1996: F Westermann; Martin Hafner; B Haier; Heribert Bohlen; Andreas Engert; M Zuehlsdorf; Volker Diehl; Hans Tesch
Interleukin 10 inhibits cytokine production of human AML cells.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(4):397-404.
1995: Volker Diehl; Markus Loeffler; Michael Pfreundschuh; U Ruehl; Dirk Hasenclever; Hiltrud Nisters-Backes; Markus Sieber; K Smith; Hans Tesch; W Geilen
Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease. German Hodgkins' Study Group (GHSG).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(9):901-10.
1995: Johannes Irsch; Nicolas Hunzelmann; Hans Tesch; H Merk; E Maggi; Anna Ruffilli; Andreas Radbruch
Isolation and characterization of allergen-binding cells from normal and allergic donors.
Immunotechnology : an international journal of immunological engineering 1995;1(2):115-25.
1995: S C Klein; Manfred Jücker; Harry F Abts; Hans Tesch
IL6 and IL6 receptor expression in Burkitt's lymphoma and lymphoblastoid cell lines: promotion of IL6 receptor expression by EBV.
Hematological oncology 1995;13(3):121-30.
1995: M Gorschlüter; Heribert Bohlen; Dirk Hasenclever; Volker Diehl; Hans Tesch
Serum cytokine levels correlate with clinical parameters in Hodgkin's disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(5):477-82.
1995: Hans Tesch; W Doerfler; Andreas Engert; M Hansmann; Andreas Radbruch; K Rajewsky; J Wolf; Volker Diehl
[Immune dysregulation and malignant lymphoma].
Der Internist 1995;36(4):367-71.
1995: Martin Hafner; Cornelia Platzer; A von Knethen; H Straub; Heribert Bohlen; M Hafner; Hans Tesch
Isolation of the human interleukin 10 promoter. Characterization of the promoter activity in Burkitt's lymphoma cell lines.
Cytokine 1995;7(1):1-7.
1994: Heribert Bohlen; Oliver Manzke; Andreas Engert; M Hertel; R Hippler-Altenburg; Volker Diehl; Hans Tesch
Differentiation of cytotoxicity using target cells labelled with europium and samarium by electroporation.
Journal of immunological methods 1994;173(1):55-62.
1994: Gerhard R F Krueger; A Guenther; R Knuefermann; U Kluppelberg; Janos Luka; G R Pearson; Dharam V Ablashi; M Juecker; Hans Tesch
Human herpesvirus-6 (HHV-6) in Hodgkin's disease: cellular expression of viral antigens as compared to oncogenes met and fes, tumor suppressor gene product p53, and interleukins 2 and 6.
In vivo (Athens, Greece) 1994;8(4):501-16.
1994: S Schmitz; Hans Tesch; Heribert Bohlen; Andreas Engert; Volker Diehl
[Chronic fatigue syndrome].
Medizinische Klinik (Munich, Germany : 1983) 1994;89(3):154-9.
1994: Manfred Jücker; A Günther; G Gradl; C Fonatsch; G Krueger; Volker Diehl; Hans Tesch
The Met/hepatocyte growth factor receptor (HGFR) gene is overexpressed in some cases of human leukemia and lymphoma.
Leukemia research 1994;18(1):7-16.
1993: Heribert Bohlen; T Hopff; Oliver Manzke; Andreas Engert; Martin Hafner; PD Wickramanayake; Volker Diehl; Hans Tesch
Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies.
Blood 1993;82(6):1803-12.
1993: Heribert Bohlen; Oliver Manzke; B Patel; G Moldenhauer; B Dörken; V von Fliedner; Volker Diehl; Hans Tesch
Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
Cancer research 1993;53(18):4310-4.
1993: Hans Tesch; A Günther; Harry F Abts; Manfred Jücker; S Klein; Gerhard R F Krueger; Volker Diehl
Expression of interleukin-2R alpha and interleukin-2R beta in Hodgkin's disease.
The American journal of pathology 1993;142(6):1714-20.
1993: Hans Tesch; Harald Stein; Volker Diehl
[Cellular and molecular biology of malignant lymphoma].
Der Internist 1993;34(2):89-96.
1993: Johannes Irsch; R Hendriks; Hans Tesch; R Schuurman; Andreas Radbruch
Evidence for a human IgG1 class switch program.
European journal of immunology 1993;23(2):481-6.
1993: Peter Volling; Markus Jungehülsing; Manfred Jücker; Hartmut Stützer; Volker Diehl; Hans Tesch
Coamplification of the hst and bcl-1 oncogenes in advanced squamous cell carcinomas of the head and neck.
European journal of cancer (Oxford, England : 1990) 1993;29A(3):383-9.
1993: Hans Tesch; Manfred Jücker; Harry F Abts; R Laumann; W D Ludwig; I Pahl
Regulation of protooncogenes and cytokine genes in acute lymphoblastic leukemia.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1993;131():239-47.
1992: Hans Tesch; A C Feller; Manfred Jücker; S Klein; H Merz; Volker Diehl
Activation of cytokines in Hodgkin's disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3 Suppl 4():13-6.
1992: K Koch; Hans Tesch; S Eidt; G Krueger; Volker Diehl
Analysis of c-myc, bcl-1 and bcl-2 translocations in human lymphoma by pulsed-field gel electrophoresis.
Leukemia & lymphoma 1992;7(5-6):463-72.
1992: Hans Tesch; Manfred Jücker; S Klein; Harry F Abts; A Günther; Gerhard R F Krueger; Volker Diehl
Hodgkin and Reed-Sternberg cells express interleukin 6 and interleukin 6 receptors.
Leukemia & lymphoma 1992;7(4):297-303.
1992: S Klein; D B Jones; Hans Tesch
In vitro differentiation of a Hodgkin's disease derived cell line.
Hematological oncology 1992;10(3-4):195-205.
1992: Manfred Jücker; Anton J M Roebroek; Josef Mautner; K Koch; Dirk Eick; Volker Diehl; Wim J M Van De Ven; Hans Tesch
Expression of truncated transcripts of the proto-oncogene c-fps/fes in human lymphoma and lymphoid leukemia cell lines.
Oncogene 1992;7(5):943-52.
1992: R Laumann; Manfred Jücker; Hans Tesch
Point mutations in the conserved regions of the p53 tumour suppressor gene do not account for the transforming process in the Jurkat acute lymphoblastic leukemia T-cells.
Leukemia 1992;6(3):227-8.
1992: Hans Tesch; M Michels; Manfred Jücker; I Pahl; S Klein; H Bading; K Moelling; Volker Diehl
Heterogeneous expression of c-myb protein in human leukemia detected by simultaneous two color flow cytometric analysis.
Leukemia research 1992;16(3):265-74.
1991: Martin Schrappe; C Pohl; Hans Tesch; Volker Diehl
[HIV-associated non-hodgkin lymphoma. Prognosis and therapeutic options].
Medizinische Klinik (Munich, Germany : 1983) 1991;86(12):646-54, 660.
1991: Hans Tesch; Bernd Lathan; Volker Diehl
[Malignant lymphomas in HIV infected patients].
Der Internist 1991;32(8):495-8.
1991: S Achten; A Behn-Krappa; Manfred Jücker; Jörg Sprengel; I Hölker; Birgit Schmitz; Hans Tesch; Volker Diehl; Walter Doerfler
Patterns of DNA methylation in selected human genes in different Hodgkin's lymphoma and leukemia cell lines and in normal human lymphocytes.
Cancer research 1991;51(14):3702-9.
1991: Stefan Kochanek; Andreas Radbruch; Hans Tesch; D Renz; Walter Doerfler
DNA methylation profiles in the human genes for tumor necrosis factors alpha and beta in subpopulations of leukocytes and in leukemias.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(13):5759-63.
1991: Manfred Jücker; Harry F Abts; Dirk Eick; G M Lenoir; Hans Tesch
Over-expression of lck in Burkitt's lymphoma cell lines.
Leukemia 1991;5(6):528-30.
1991: Hans Tesch; C Fonatsch; Volker Diehl
Rearrangements of immunoglobulin- and BCR-genes in chronic myeloid leukemia.
In vivo (Athens, Greece) 1991;5(3):233-8.
1991: Harry F Abts; Manfred Jücker; Volker Diehl; Hans Tesch
Human chronic lymphocytic leukemia cells regularly express mRNAs of the protooncogenes lck and c-fgr.
Leukemia research 1991;15(11):987-97.
1990: Volker Diehl; C von Kalle; C Fonatsch; Hans Tesch; M Jüecker; M Schaadt
The cell of origin in Hodgkin's disease.
Seminars in oncology 1990;17(6):660-72.
1990: K Koch; Manfred Jücker; M Michels; Wim J M Van De Ven; Hans Tesch
Polymorphism at the FES locus detected by PFGE.
Nucleic acids research 1990;18(19):5918.
1990: Hans Tesch; R Fürbass; J Casper; J Lyons; C R Bartram; H J Schmoll; D L Bronson
Cellular oncogenes in human teratocarcinoma cell lines.
International journal of andrology 1990;13(5):377-88.
1990: M Michels; E Schumacher; Volker Diehl; Hans Tesch
[Plasmocytoma: immunology and molecular genetics].
Medizinische Klinik (Munich, Germany : 1983) 1990;85(9):548-54.
1990: Manfred Jücker; M Schaadt; Volker Diehl; S Poppema; D Jones; Hans Tesch
Heterogeneous expression of proto-oncogenes in Hodgkin's disease derived cell lines.
Hematological oncology 1990;8(4):191-204.
1990: Hans Tesch; Thomas Herrmann; Harry F Abts; T Diamantstein; Volker Diehl
High affinity IL-2 receptors on a Hodgkin's derived cell line.
Leukemia research 1990;14(11-12):953-60.
1990: Hans Tesch; Rudolph Zankovich; C Fonatsch; Volker Diehl
Analysis of bcr rearrangements in primary (essential) thrombocythaemia.
Leukemia research 1990;14(3):241-6.
1990: Hans Tesch; P May; G R Krueger; R Fischer; Volker Diehl
Analysis of immunoglobulin, T cell receptor and bcr rearrangements in human malignant lymphoma and Hodgkin's disease.
Oncology 1990;47(3):215-23.
1989: Harry F Abts; M Emmerich; S Miltenyi; Andreas Radbruch; Hans Tesch
CD20 positive human B lymphocytes separated with the magnetic cell sorter (MACS) can be induced to proliferation and antibody secretion in vitro.
Journal of immunological methods 1989;125(1-2):19-28.
1989: Hans Tesch; Harry F Abts; Manfred Jücker; K Mays; G Lenoir; Volker Diehl
Expression of c-fgr in EBV positive and negative B cell tumors.
Leukemia 1989;3(12):897-8.
1989: Frank Berthold; Gerhard R F Krueger; Hans Tesch; W Hiddemann
Monoclonal B cell proliferation in lymphoproliferative disease associated with herpes virus type 6 infection.
Anticancer research 1989;9(6):1511-8.
1989: Gerhard R F Krueger; M Manak; N Bourgeois; Dharam V Ablashi; S Z Salahuddin; S S Josephs; A Buchbinder; Robert C Gallo; Frank Berthold; Hans Tesch
Persistent active herpes virus infection associated with atypical polyclonal lymphoproliferation (APL) and malignant lymphoma.
Anticancer research 1989;9(6):1457-76.
1989: M Schaadt; H Burrichter; Michael Pfreundschuh; E Schell-Frederick; Hans Tesch; C Fonatsch; Harald Stein; Volker Diehl
Biology of Hodgkin cell lines.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1989;117():53-61.
1988: Hans Tesch; Manfred Jücker; M H Falk; G W Bornkamm; D B Jones; Volker Diehl
Molecular analysis of Hodgkin's disease-derived cell lines.
Hematological oncology 1988;6(3):223-31.
1988: Hans Tesch; K Olek; J Geisel; Wim J M Van De Ven; Manfred Jücker
RFLP of the human c-fes proto-oncogene.
Nucleic acids research 1988;16(9):4193.
1988: Peter Volling; Markus Jungehülsing; Hans Tesch; Eberhard Stennert
[Oncogenes in squamous epithelial cancers in the area of the head and neck].
Laryngologie, Rhinologie, Otologie 1988;67(4):160-4.